Chemically triggered drug release from an antibody-drug conjugate leads to potent antitumour activity in mice

Raffaella Rossin, Ron M. Versteegen, Jeremy Wu, Alisher Khasanov, Hans J. Wessels, Erik J. Steenbergen, Wolter ten Hoeve, Henk M. Janssen, Arthur H.A.M. van Onzen, Peter J. Hudson, Marc S. Robillard

Onderzoeksoutput: Bijdrage aan tijdschriftTijdschriftartikelAcademicpeer review

60 Citaten (Scopus)
101 Downloads (Pure)

Samenvatting

Current antibody-drug conjugates (ADCs) target internalising receptors on cancer cells leading to intracellular drug release. Typically, only a subset of patients with solid tumours has sufficient expression of such a receptor, while there are suitable non-internalising receptors and stroma targets. Here, we demonstrate potent therapy in murine tumour models using a non-internalising ADC that releases its drugs upon a click reaction with a chemical activator, which is administered in a second step. This was enabled by the development of a diabody-based ADC with a high tumour uptake and very low retention in healthy tissues, allowing systemic administration of the activator 2 days later, leading to efficient and selective activation throughout the tumour. In contrast, the analogous ADC comprising the protease-cleavable linker used in the FDA approved ADC Adcetris is not effective in these tumour models. This first-in-class ADC holds promise for a broader applicability of ADCs across patient populations.

Originele taal-2Engels
Artikelnummer1484
Aantal pagina's11
TijdschriftNature Communications
Volume9
Nummer van het tijdschrift1
DOI's
StatusGepubliceerd - 1 dec 2018

Vingerafdruk Duik in de onderzoeksthema's van 'Chemically triggered drug release from an antibody-drug conjugate leads to potent antitumour activity in mice'. Samen vormen ze een unieke vingerafdruk.

  • Citeer dit

    Rossin, R., Versteegen, R. M., Wu, J., Khasanov, A., Wessels, H. J., Steenbergen, E. J., ten Hoeve, W., Janssen, H. M., van Onzen, A. H. A. M., Hudson, P. J., & Robillard, M. S. (2018). Chemically triggered drug release from an antibody-drug conjugate leads to potent antitumour activity in mice. Nature Communications, 9(1), [1484]. https://doi.org/10.1038/s41467-018-03880-y